AAP
REGN icon

Arax Advisory Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Arax Advisory Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Buy
9,563
+8,950
+1,460% +$6.09M 0.04% 436
2026
Q1 		$471K Sell
613
-375
-38% -$287K 0.01% 676
2025
Q4 		$763K Sell
988
-8,454
-90% -$5.74M 0.02% 456
2025
Q3 		$5.31M Buy
9,442
+9,361
+11,557% +$5.29M 0.08% 216
2025
Q2 		$42.5K Buy
81
+19
+31% +$10.6K ﹤0.01% 1317
2025
Q1 		$39.3K Buy
62
+48
+343% +$33K ﹤0.01% 1044
2024
Q4 		$9.97K Sell
14
-28
-67% -$23.5K ﹤0.01% 1493
2024
Q3 		$44.2K Hold
42
– – ﹤0.01% 767
2024
Q2 		$44.1K Buy
42
+28
+200% +$27.1K ﹤0.01% 707
2024
Q1 		$13.5K Hold
14
– – ﹤0.01% 731
2023
Q4 		$12.3K Sell
14
-1
-7% -$823 ﹤0.01% 732
2023
Q3 		$12.3K Buy
15
+1
+7% +$786 ﹤0.01% 675
2023
Q2 		$10.1K Sell
14
-1
-7% -$771 ﹤0.01% 705
2023
Q1 		$12.3K Buy
15
+4
+36% +$3.02K ﹤0.01% 656
2022
Q4 		$7.94K Buy
11
+1
+10% +$738 ﹤0.01% 683
2022
Q3 		$7K Buy
10
+6
+150% +$3.78K ﹤0.01% 723
2022
Q2 		$2K Buy
4
+2
+100% +$1.3K ﹤0.01% 962
2022
Q1 		$1K Sell
2
-2
-50% -$1.26K ﹤0.01% 1079
2021
Q4 		$3K Buy
4
+2
+100% +$1.23K ﹤0.01% 844
2021
Q3 		$1K Buy
+2
New +$1.24K ﹤0.01% 934
2018
Q3 		– Sell
-10
Closed -$3K – 710
2018
Q2 		$3K Sell
10
-11
-52% -$3.44K ﹤0.01% 426
2018
Q1 		$7K Sell
21
-65
-76% -$22.6K ﹤0.01% 350
2017
Q4 		$32K Sell
86
-11
-11% -$4.46K 0.01% 245
2017
Q3 		$43K Sell
97
-10
-9% -$4.76K 0.02% 227
2017
Q2 		$53K Buy
107
+56
+110% +$24.5K 0.03% 222
2017
Q1 		$19K Buy
51
+45
+750% +$16.7K 0.01% 285
2016
Q4 		$2K Buy
+6
New +$2.28K ﹤0.01% 483

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arax Advisory Partners's REGN Position: Q2 2026 in Review

Arax Advisory Partners increased its Regeneron Pharmaceuticals (REGN) stake by 1,460% in Q2 2026, buying an estimated $6.09M and bringing the position to 9,563 shares worth $5.96M. The position accounts for 0.04% of the portfolio, ranked #436.

Arax Advisory Partners first reported a position in REGN in Q4 2016 and has held it in 27 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arax Advisory Partners held 9,563 shares of Regeneron Pharmaceuticals worth $5.96M as of Q2 2026.
  • Arax Advisory Partners bought 8,950 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.09M.
  • Regeneron Pharmaceuticals made up 0.04% of Arax Advisory Partners's portfolio in Q2 2026, its #436 holding.
  • Arax Advisory Partners first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.